Role of ACE Inhibitors in Patients with Diabetes Mellitus

Drugs

Volumn 61, Issue 13, 2001, Pages 1883-1892

  Cordonnier, Daniel J ^a   Zaoui, Philippe ^a   Halimi, Serge ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HEART DISEASE; HUMAN; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HEART DISEASES; HUMANS; KIDNEY DISEASES;

EID: 0035226439     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161130-00001     Document Type: Review

References (75)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications. Estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl. 5: 1-15
2. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-9
4. Turner RC. Millns H, Neil HAW, et al. for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823-8
5. Fioretto P, Steffes MW. Sutherland DES, et al. Reversal of diabetic nephropathy by pancreas transplantation. N Engl J Med 1998; 339:69-75
6. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-25
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
8. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
9. Gaede P, Vedel P, Parving H, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22
10. Zatz R, Dunn BR. Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmalogical amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-30
11. Anderson S. Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526-36
12. Björk S. Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition an renal function in patients with diabetic nephropathy. BMJ 1986; 293: 471-4
13. Laffel LMB, McGill JB, Bans DJ. The beneficial effect of angiotensin-Converting Enzyme Inhibition with Captopril on diabetic nephropathy in Normotensive IDDM patients with Microalbuminuria. Am J Med 1995; 99: 497-504
14. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92
15. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of Angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
16. Kasiske BL, Kalil RSN, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38
17. Bohlen L, Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 848-928
18. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996; 156: 286-9
19. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253-63
20. Cordonnier DJ. Glomerular involvement in type 2 diabetes. Is it all glomerulosclerosis [editorial|? Nephrol Dial Transpl 1996; 11: 936-8
21. Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and Enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney lnt 1996; 49 Suppl. 55: 91-3
22. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effecrs, of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy [editorial]. Lancet 2000; 355: 253-9
23. Sato H, Iwano M, Akai Y, et al. Increased excretion of urinary transforming growth factor β1 in patients with diabetic nephropathy. Am J Nephrol 1988; 18: 490-94
24. Baricos WH, Cortez SL, Deboisblanc M, et al. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 790-5
25. Ma J, Nishimura H, Fogo A, et al. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998; 53: 937-44
26. Sharma K, Eltayeb BO, McGowan TA, et al. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34: 818-23
27. Wang SN, Hirschberg R. Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy. Nephrol Dial Transplant 1999; 14: 2072-4
28. Abbate M, Zoja C, Rottoli D, et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 1999; 10: 790-5
29. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999: 56: 1627-37
30. Morelli E, Loon N, Meyer TW, et al. Effects of converting enzyme inhibitors on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76-82
31. Hansson L. Lindholm L, Nisaken L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-16
32. Capes SE, Gerstein HC, Negassa A, et al. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000; 23: 177-80
33. Cohn JN. Drug therapy: the management of chronic heart failure. N Engl J Med 1996; 335: 490-8
34. Delcourt C, Villatte-Cathelineau B, Vauzelle-Kervroedan F, et al. Clinical correlates of advanced retinopathy in type II diabetic patients: Implications for screening. J Clin Epidemiol 1996; 49: 679-85
35. American Diabetes Association: diahelic retinopathy. Diabetes Care 1998: 21 Suppl. 1: 47-9
36. Chaturvedi N, Sjolie A, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31
37. Barnett AH. The heart outcome protection evaluation (HOPE) study: relevance to ophtalmolugical practice? Eye 2000: 14: 1-2
38. Larsen M, Hommel E, Parving HH, et al. Protective effect of captopril on the blood-retina barrier in normotensive insulindependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophtalmol 1990; 228: 505-9
39. Jackson WE, Holmes DL, Garg SK, et al. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophtalmol 1992; 24: 99-103
40. Feman SS. Mericle RA, Reed GW, et al. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci 1993; 305: 280-4
41. Danser AH, Derkx FH, Admiraal PJ, et al. Angiotensin levels in the eye. Invest Ophtalmol Vis Sci 1994; 35: 1008-18
42. Williams B. Angiotensin II, VEGF and diabetic retinopathy [letter]. Lancet 1998; 351; 836-7
43. Forrest KYZ, Maser RE, Pamhianco G, et al. Hypertension as a risk factor for diabetic neuropathy. Diabetes 1997; 46: 665-70
44. Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997; 46 Suppl. 2: S50-53
45. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streopozolocindiabetic rats. Diabetologia 1992; 35: 12-18
46. Al-Memar A, Wimalaratna HSK, Millward BA. Lisinopril improves nerve function in insulin-dependant diabetic patients with neuropathy: a preferential effect on small fibres. Diabet Med 1996; 13 (838): 90
47. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-81
48. Jackson EK, Garrison JC, Renin and angiotensin. In: Goodman & Gilman's The pharmacological basis of therapeutics. 9th ed. USA: Mc Graw-Hill. 1996: 733-58
49. Seghieri G, Yin W, Boni C, et al. Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type II diabetic patients. Diabet Med 1992; 9: 732-8
50. Bak J, Gerdes L, Sorensen N, et al. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 1992; 92: 69-72
51. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73
52. New JP, Bilous RW. Insulin sensitivity in type II diabetic patients treated with insulin. Diabet Med 2000; 17: 134-40
53. Herings RM, De Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195-8
54. Keilani T, Schimeter WA, Levin ML, et al. Improvement of lipid abnormalities associated with proteinuna using fosinopril. an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993; 118: 246-254
55. Courrèges JP, Bacha J, Aboud E. Prevalence and profile of reno vascular disease in diabetic type 2 with severe hypertension. J Hypertens 1997; 15: 1348-51
56. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 1996; 19: 1051-61
57. Le Pen CI, Petitjean Ph, Levy P, et al. L'évaluation économique de l'apport du captopril dans le traitement de la néphropathie diabétique: une approche coût-efficaeité. Nephrol 1997; 17: 321-6
58. Lewis V, Kloer P, Prasad N, et al. The HOPE study and diabetes [letter]. Lancet 2000; 355: 1182
59. Fegan G, Ward D, Clarke L, et al. The HOPE study and diabetes [letler]. Lancet 2000; 355: 1182-3
60. Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy J Am Soc Nephrol 2000; 11: 690-9
61. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in patients of proteinuric insulin dependent diabetics. BMJ 1987; 295: 515-7
62. Pettitt DJ, Saad MF, Benett PH, et al. Familial predisposition to renal disease in two generations of pima indians with type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia 1990; 33: 438-43
63. Fogarty DG, Rich SS, Hanna L, et al. Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int 2000; 57: 250-57
64. Cambien F. The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infaretion. Clin Genet 1994; 46: 94-101
65. Hsieh MC, Lin SR, Hsieh TJ, et al. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant 2000; 15: 1008-13
66. Marre M, Jeunemaitre X, Gallois T, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin dependent diabetes: Génétique de la néphropathie diabétique (GENEDIAB) study group. J Clin Invest 1997; 99: 1585-95
67. Fujisawa T, Ikegami H,Kawaguchi Y, et al. Meta analysis of association of insertion/deletion polymorphism of angiotensin I converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53
68. Esnault V, Renoprotective properties of angiotensin-converting enzyme inhibitors: proofs and limits? [letter]. Nephron 2000; 85: 183-4
69. Bos E, De Zeeuw D, Parving HH, et al. Role of patients factors in therapy resistance to antiproteinurie therapy in non diabetic and diabetic nephropathy. Kidney Int 2000: 57 Suppl. 75: S32-7
70. Anonymous. Should all type I diabetic patient with microalbuminuria receive an ACE Inhibitor? Ann Intern Med 2001; 134: 370-9
71. Pitt B, Poole-Wilson A, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7
72. Morgensen CE, Neldam S, Tikkanen I. Randomised controlled trial of dual blockade of renin-angiotensin system patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321 (7274): 1440-4
73. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patienls with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
74. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
75. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2000; 345 (12): 870-8